Caly Chien

2.1k total citations · 1 hit paper
36 papers, 1.5k citations indexed

About

Caly Chien is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Caly Chien has authored 36 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 10 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Caly Chien's work include Prostate Cancer Treatment and Research (13 papers), Hormonal and reproductive studies (8 papers) and Radiopharmaceutical Chemistry and Applications (7 papers). Caly Chien is often cited by papers focused on Prostate Cancer Treatment and Research (13 papers), Hormonal and reproductive studies (8 papers) and Radiopharmaceutical Chemistry and Applications (7 papers). Caly Chien collaborates with scholars based in United States, Belgium and Canada. Caly Chien's co-authors include Dennis M. Grasela, Richard E. Nettles, Nicholas A. Meanwell, Richard J. Colonno, Chunfu Wang, Van N. Nguyen, Lawrence G. Hamann, Donald R. O’Boyle, Julie A. Lemm and Jay O. Knipe and has published in prestigious journals such as Nature, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Caly Chien

34 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

2010 689 citations Min Gao, Richard E. Nettles et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Caly Chien United States	18	585	496	296	273	241	36	1.5k
Michio Kato Japan	22	973 1.7×	1.0k 2.0×	110 0.4×	106 0.4×	449 1.9×	104	1.9k
Daniel F. Schafer United States	24	1.5k 2.5×	1.2k 2.4×	89 0.3×	132 0.5×	275 1.1×	56	2.5k
Milton G. Mutchnick United States	20	645 1.1×	703 1.4×	81 0.3×	85 0.3×	180 0.7×	78	1.4k
Moritoshi Kinoshita Japan	28	341 0.6×	498 1.0×	200 0.7×	121 0.4×	1.0k 4.2×	75	2.3k
Sarah Allegra Italy	16	221 0.4×	203 0.4×	60 0.2×	248 0.9×	131 0.5×	59	801
José D. Debes United States	22	601 1.0×	479 1.0×	458 1.5×	211 0.8×	596 2.5×	89	1.7k
Ethan M. Weinberg United States	20	570 1.0×	605 1.2×	64 0.2×	82 0.3×	415 1.7×	51	1.5k
Hong Tang China	25	1.3k 2.2×	1.5k 3.0×	97 0.3×	150 0.5×	752 3.1×	138	2.6k
Linh T. Nguyen United States	22	230 0.4×	176 0.4×	317 1.1×	40 0.1×	412 1.7×	71	1.3k
David Chang United States	25	608 1.0×	164 0.3×	415 1.4×	261 1.0×	1000 4.1×	68	2.9k

Countries citing papers authored by Caly Chien

Since Specialization

Citations

This map shows the geographic impact of Caly Chien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caly Chien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caly Chien more than expected).

Fields of papers citing papers by Caly Chien

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Caly Chien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caly Chien. The network helps show where Caly Chien may publish in the future.

Co-authorship network of co-authors of Caly Chien

This figure shows the co-authorship network connecting the top 25 collaborators of Caly Chien. A scholar is included among the top collaborators of Caly Chien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Caly Chien. Caly Chien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhou, Xiaofei, Boris Grinshpun, Adekemi Taylor, et al.. (2025). Population Pharmacokinetics of Fruquintinib, a Selective Oral Inhibitor of VEGFR ‐1, ‐2, and ‐3, in Patients with Refractory Metastatic Colorectal Cancer. The Journal of Clinical Pharmacology. 65(7). 873–884. 2 indexed citations

Dasari, Arvind, Erika Hamilton, Gerald S. Falchook, et al.. (2023). A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors. Investigational New Drugs. 41(3). 421–430. 1 indexed citations

Wang‐Gillam, Andrea, et al.. (2023). Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States. Investigational New Drugs. 41(6). 851–860. 7 indexed citations

T’jollyn, Huybrecht, Caly Chien, Angela Lopez‐Gitlitz, et al.. (2022). Efficacy and safety exposure–response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study. Cancer Chemotherapy and Pharmacology. 89(5). 629–641. 10 indexed citations

Dasari, Arvind, Alberto Sobrero, James C. Yao, et al.. (2021). FRESCO-2: A Global Phase III Study Investigating the Efficacy and Safety of Fruquintinib in Metastatic Colorectal Cancer. Future Oncology. 17(24). 3151–3162. 31 indexed citations

Posadas, Edwin M., Kim N., Ronald de Wit, et al.. (2020). Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study. Clinical Cancer Research. 26(14). 3517–3524. 12 indexed citations

Ouellet, Danièle, Caly Chien, Hiroji Uemura, et al.. (2020). Efficacy and Safety Exposure–Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 26(17). 4460–4467. 17 indexed citations

Bergh, An Van den, Jan Snoeys, Loeckie De Zwart, et al.. (2020). Pharmacokinetic Drug–Drug Interaction of Apalutamide, Part 2: Investigating Interaction Potential Using a Physiologically Based Pharmacokinetic Model. Clinical Pharmacokinetics. 59(9). 1149–1160. 16 indexed citations

Vries, Ronald P. de, Frank Jacobs, Geert Mannens, et al.. (2019). Apalutamide Absorption, Metabolism, and Excretion in Healthy Men, and Enzyme Reaction in Human Hepatocytes. Drug Metabolism and Disposition. 47(5). 453–464. 29 indexed citations

10.

Chien, Caly, et al.. (2019). Population Pharmacokinetics of Apalutamide and its Active Metabolite N-Desmethyl-Apalutamide in Healthy and Castration-Resistant Prostate Cancer Subjects. Clinical Pharmacokinetics. 59(2). 229–244. 17 indexed citations

11.

Alyamani, Mohammad, Hamid Emamekhoo, Sunho Park, et al.. (2018). HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer. Journal of Clinical Investigation. 128(8). 3333–3340. 42 indexed citations

12.

Tresckow, Bastian von, Franck Morschhauser, Vincent Ribrag, et al.. (2015). An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma. Clinical Cancer Research. 21(8). 1843–1850. 94 indexed citations

13.

N., Kim, Jennifer L. Spratlin, Christian Kollmannsberger, et al.. (2015). Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration‐resistant prostate cancer. The Journal of Clinical Pharmacology. 55(12). 1406–1414. 82 indexed citations

14.

Genovese, Mark C., Elizabeth C. Hsia, Stanley M. Belkowski, et al.. (2015). Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy. The Journal of Rheumatology. 42(10). 1752–1760. 49 indexed citations

15.

Inoue, Kouichi, Akira Shishido, Nicole Vaccaro, et al.. (2014). Pharmacokinetics of abiraterone in healthy Japanese men: dose-proportionality and effect of food timing. Cancer Chemotherapy and Pharmacology. 75(1). 49–58. 15 indexed citations

16.

Brown, Jonathan, Caly Chien, Peter Timmins, et al.. (2013). Compartmental Absorption Modeling and Site of Absorption Studies to Determine Feasibility of an Extended-Release Formulation of an HIV-1 Attachment Inhibitor Phosphate Ester Prodrug. Journal of Pharmaceutical Sciences. 102(6). 1742–1751. 44 indexed citations

17.

Gao, Min, Richard E. Nettles, Makonen Belema, et al.. (2010). Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 465(7294). 96–100. 689 indexed citations breakdown →

18.

Morrison, Janna L., et al.. (2004). Chronic Maternal Fluoxetine Infusion in Pregnant Sheep: Effects on the Maternal and Fetal Hypothalamic-Pituitary-Adrenal Axes. Pediatric Research. 56(1). 40–46. 36 indexed citations

19.

Morrison, Janna L., et al.. (2002). Effect of Maternal Fluoxetine Administration on Uterine Blood Flow, Fetal Blood Gas Status, and Growth. Pediatric Research. 51(4). 433–442. 61 indexed citations

20.

Morrison, Janna L., et al.. (2001). Fetal behavioural state changes following maternal fluoxetine infusion in sheep. Developmental Brain Research. 131(1-2). 47–56. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact